SHR-1806
SHR-1806 is a OX40 agonist and a NF-κB activator, with antitumor activity. SHR-1806 mediates ADCC and CDC effects, enhances the function and expansion of effector T cells, suppresses regulatory T cells, and increases γ-interferon secretion. SHR-1806 exhibits typical pharmacokinetic characteristics and favorable safety profiles. SHR-1806 can be used in studies related to solid tumors and colon cancer.
Para uso exclusivo en investigación. No vendemos a pacientes.
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
Ver todos los productos específicos de isoformas Orexin Receptor (OX Receptor)
More
Actividad biológica
Descripciòn
Species Reactivity
Human
In Vitro
SHR-1806 (0.1-10000 ng/mL) binds specifically and potently to human and rhesus monkey OX40 in an ELISA format, with comparable EC50 values of 61.47 ng/mL and 60.80 ng/mL, respectively[1].
SHR-1806 (0.0001-100 nM; 1 h) exhibits potent, specific binding to OX40-expressing CHOK1-hOX40 cells and activated human T cells, with EC50 values of 1.99 nM and 0.20 nM, respectively, and no binding to activated mouse or rat T cells[1].
SHR-1806 (0.01-100 nM; 1 h) potently blocks the interaction between OX40 and OX40L in CHOK1-hOX40L cells, with an IC50 of 12.51 nM[1].
SHR-1806 (0.01-100 nM; 5 h) potently activates NF-κB signaling in Jurkat-NF-κB-Luc-hOX40 cells co-cultured with Raji cells, with an EC50 of 0.36 nM, demonstrating greater potency than GPX4[1].
SHR-1806 (1-1000 ng/mL; 72 h) potently activates human memory CD4+ T cells to secrete IFN-γ, with greater activity than the reference antibody GPX4 at equivalent concentrations[1].
SHR-1806 (0.01-100 nM; 15 min) exhibits potent ADCC activity against HEK293-hOX40 cells, with an EC50 of 0.01 nM, demonstrating superior potency compared to GPX4[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
SHR-1806 (1 mg/kg; i.p.; every 3 days; 4 total doses) at 1 mg/kg suppresses local and distant MC38 tumor growth in human OX40 knock-in mice, and enhances intratumoral effector T cell responses, with synergistic antitumor activity when combined with a TLR7 agonist[1].
SHR-1806 (0.3-1 mg/kg; i.p.; twice weekly; 3 doses then 3 additional doses) (dose-adjusted from 0.3 to 1 mg/kg) exhibits antitumor efficacy against MC38/H-11 tumors in human OX40 knock-in mice, with enhanced activity when combined with a PD-L1 inhibitor[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Human OX40 knock-in mice (maintained under SPF conditions)[1]
-
Dosage:0.3 mg/kg; 1 mg/kg; 3 mg/kg
-
Administration:i.p.; every 3 days; 6 total doses
-
Result:Demonstrated dose-dependent tumor growth inhibition with TGI values of 47.3%, 82.4%, and 90.5% at 0.3, 1, and 3 mg/kg, respectively.
Achieved a higher TGI (90.5%) than reference antibody GPX4 (78.2% TGI) at 3 mg/kg.
Increased the percentage of intratumoral CD3+ T cells, CD8+ T cells, and CD4+ T cells, and reduced the percentage of intratumoral regulatory T cells (Tregs) at 3 mg/kg compared to the control group.
Caused no significant body weight changes during treatment.
-
Animal Model:Human OX40 knock-in mice (maintained under SPF conditions)[1]
-
Dosage:1 mg/kg
-
Administration:i.p.; every 3 days; 4 total doses
-
Result:Suppressed tumor growth in both right and left flank tumors as monotherapy.
Achieved TGI of 89.0% for right-side tumors and 83.6% for left-side tumors on Day 9 post-treatment when combined with intratumoral SHR2150 (TLR7 agonist).
Increased intratumoral CD3+ T cell infiltration and the percentage of proliferating CD3+CD8+Ki67+ T cells compared to controls as monotherapy.
Caused no significant body weight changes during treatment.
Gene ID
Accession
Target
TNFRSF4/OX40/CD134
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Aplicación
ELISA, FACS, Functional assay
Chemical Information
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
[1]. Zhang J, et al. SHR-1806, a robust OX40 agonist to promote T cell-mediated antitumor immunity. Cancer Biol Ther. 2024;25(1):2426305. [Content Brief]
[2]. Yuan Z, et al. OX40/OX40L: a new target for tumor immunotherapy and its clinical research progress. Front Oncol. 2026;15:1730620. Published 2026 Jan 5. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)